Mainz Biomed (NASDAQ:MYNZ) Sees Large Decline in Short Interest

Mainz Biomed (NASDAQ:MYNZ) was the target of a significant decrease in short interest in the month of November. As of November 30th, there was short interest totalling 88,000 shares, a decrease of 97.5% from the November 15th total of 3,570,000 shares. Based on an average daily volume of 96,100 shares, the days-to-cover ratio is presently 0.9 days. Currently, 5.5% of the company’s stock are short sold.

Mainz Biomed Stock Up 6.3 %

Shares of NASDAQ:MYNZ traded up $0.33 on Thursday, hitting $5.60. 306,406 shares of the company traded hands, compared to its average volume of 37,983. The stock has a 50 day simple moving average of $9.72 and a 200-day simple moving average of $14.29. The company has a market cap of $1.68 million, a PE ratio of -0.09 and a beta of 0.06. Mainz Biomed has a 52 week low of $4.30 and a 52 week high of $53.60.

Analyst Ratings Changes

Separately, HC Wainwright cut Mainz Biomed from a “buy” rating to a “neutral” rating in a research report on Monday, November 25th.

Mainz Biomed Company Profile

Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer.